Micropuncture Study of the Effect of Various Diuretics on Sodium Reabsorption by the Proximal Tubules of the Dog

Total Page:16

File Type:pdf, Size:1020Kb

Micropuncture Study of the Effect of Various Diuretics on Sodium Reabsorption by the Proximal Tubules of the Dog Micropuncture study of the effect of various diuretics on sodium reabsorption by the proximal tubules of the dog. J H Dirks, … , W J Cirksena, R W Berliner J Clin Invest. 1966;45(12):1875-1885. https://doi.org/10.1172/JCI105492. Research Article Find the latest version: https://jci.me/105492/pdf Journal of Clinical Investigation Vol. 45, No. 12, 1966 Micropuncture Study of the Effect of Various Diuretics on Sodium Reabsorption by the Proximal Tubules of the Dog * JOHN H. DIRKS,t WILLIAM J. CIRKSENAt AND ROBERT W. BERLINER § WITH THE TECHNICAL ASSISTANCE OF NORDICA GREEN (From the Laboratory of Kidney and Electrolyte Metabolism, National Heart Institute, Bethesda, Md.) The precise sites of action of various diuretics ulin ratios are compared for each tubule. Re- within the nephron have been the subject of nu- peated collections from the same tubules do not merous investigations and considerable debate for appreciably alter tubule fluid reabsorption during several decades. Inhibition of sodium transport in continued hydropenia or continued saline infusion. the proximal tubule has, at one time or another, Acute saline infusion, however, markedly de- been considered to play a major role in the ac- pressed sodium reabsorption by the proximal tu- tion of virtually every group of diuretics. How- bule, an effect that was independent of changes in ever, such actions on the proximal tubules have glomerular filtration rate and occurred in the pres- been inferred only from indirect evidence. The ence of high circulating levels of mineralocorticoid technique of micropuncture allows a more direct hormones and vasopressin. This effect of acute evaluation of the effects of pharmacologic agents salt loading on reabsorption in the proximal tu- on sodium reabsorption by the proximal tubules. bule is thought to be mediated by some unknown The exploration by micropuncture technique of humoral agent (5-7) and has also been shown to the effects of diuretics on various portions of the occur in the rat (8). The reabsorption of fluid nephron is as yet very limited. Carbonic anhy- undergoes a considerable redistribution from prox- drase inhibitors have been shown to impair acidi- imal to distal segments after saline infusion. This fication in the proximal convoluted tubules in the makes it difficult to assess the localization of the rat (1, 2). Recently Deetjen (3) and Malnic, action of a diuretic from the magnitude of the diu- Vieira, and Enokibara (4) have examined the resis produced, since the fraction of the filtered effect of the new sulfonamide diuretic furosemide sodium that is reabsorbed in the various nephron on fluid reabsorption in the proximal tubule. segments may vary so extensively. It furthermore For the detection of the effects of interventions makes necessary careful attention to the state of on reabsorption by the tubules, a considerable ad- hydration in evaluating any changes detected in vantage accrues from repeated collections from reabsorption in the proximal tubule, since differ- the same site in the tubules, a procedure used in ences in hydration can in themselves produce recently reported studies (5). Identical convolu- marked changes in reabsorption. tions of proximal tubules are sampled during each In the studies to be reported here we have used experimental phase, and changes in sodium reab- the technique of collections from the same tubule sorption as measured by tubule fluid to plasma in- segments in dogs before and after administration of diuretics. In most of the studies, the dogs were * Submitted for publication May 24, 1966; accepted hydropenic throughout, but a few were infused August 30, 1966. Presented in part at the Eastern Section of the Ameri- with saline before the control periods, and in can Federation for Clinical Research, New York, N. Y., others sufficient isotonic saline solution was ad- December 3, 1965. ministered to replace losses due to diuresis. Al- t Present address: Department of Medicine, Royal Vic- though the methods were sensitive enough to de- toria Hospital, Montreal 2, Canada. tect the effects of small doses of mannitol, none t Special Fellow, Office of the Surgeon General, De- partment of the Army, Washington, D. C. of the other diuretics was found to yield signifi- § Address requests for reprints to Dr. Robert W. Ber- cant depression of reabsorption in the proximal liner, National Heart Institute, Bethesda, Md. 20014. convoluted tubule. 1875 1876 J. H. DIRKS, W. J. CIRKSENA, AND R. W. BERLINER Methods The following experiments with diuretics were con- ducted. Studies were performed on mongrel dogs weighing Mannitol. Graded intravenous infusions of mannitol 10 to 30 kg. The anesthesia, inulin infusion, and surgi- were used to assess the sensitivity of the technique for cal preparation of the dogs for clearances and micropunc- the detection of depressed fluid reabsorption by the ture were identical to those previously reported (5, 9, proximal convoluted tubules. Mannitol was infused into 10). Collections from convolutions of proximal tubules a leg vein at various flow rates (2 to 10.7 ml per min- were first made during a control period, and the precise ute) and at varying concentrations (5, 10, and 20%) in site of micropuncture was carefully marked in each case eight hydropenic dogs. This resulted in the excretion of with nigrosine dye layered on adjacent tubules. A dose 2 to 46% of the volume of glomerular filtrate (V/GFR) of a diuretic agent sufficient to produce a maximal 1 during resampling of previously punctured tubules. In effect was then administered intravenously. This initial four hydropenic dogs the repeat collections were done dose was followed by an infusion delivering the same in periods when V/GFR fell in the range of 10 to 46%. amount of drug per hour. When the urine flow had in- In four hydropenic dogs, repeat collections were made creased to several times the control rate, samples were when urine flow was 2 to 9% of glomerular filtration obtained from the same proximal tubule convolutions. rate. Collections of fluid from convolutions of proximal tu- Ethacrynic acid. Initial collections were performed in bules were made as described previously (5). The mi- six hydropenic dogs. Ethacrynic acid2 was then ad- cropipette, filled to the tip with colored mineral oil, was ministered intravenously in doses of 1 to 5 mg per kg inserted into a tubule, and a small amount of oil was in- with an equal hourly infusion rate. In five dogs, initial jected into the lumen. The oil drop was permitted to flow collections were performed after initial saline loading as distally, and tubule fluid was allowed to flow spontane- described for the saline controls. Ethacrynic acid was ously into the pipette. After the administration of diu- then administered as above, and the fluid loss resulting retics, the intratubular pressure was increased; conse- from the diuresis was replaced with intravenous infusion quently, the samples were analyzed only if the oil drop of an equal volume of isotonic saline solution. A single remained stationary or moved distally while in view. experiment in which the initial collections were carried In this way, the possibility of retrograde collections was out in hydropenia but in which the fluid losses were re- averted. Inulin in plasma and urine was determined by placed with isotonic saline was combined with this the anthrone method of Fiuhr, Kaczmarczyk, and Kriitt- latter group. gen (12), and filtration rates were calculated for 15- Chlormerodrin. Three dogs were loaded with 10 g minute periods during the micropuncture procedure. ammonium chloride 18 hours before the experiment. Con- Inulin in tubule fluid was determined by a modification of trol collections were performed in hydropenia, and then the microanthrone method (13, 14) as previously de- chlormerodrin was administered intravenously as a prim- scribed in detail (5) ; the method yielded reproducibility ing dose of 2 mg Hg per kg with an equal hourly infu- with a standard deviation of 4.7%o. Tubule fluid to sion rate. Collections were repeated when diuresis had plasma (TF/P) inulin ratios were calculated with the increased the flow rate severalfold over control values. plasma inulin interpolated to the midpoint of the sample In three dogs initial collections were obtained during sa- collection when there were changes in plasma inulin line loading as described and then chlormerodrin was concentration. administered as above. The losses due to diuresis were Controls. The results of control re-collection during replaced by the intravenous infusion of roughly equal continued hydropenia (thirsted 18 hours) or continued volumes of isotonic saline solution. In one dog, the saline infusion have' been reported (5). Additional con- diuretic-induced fluid losses were similarly replaced af- trols obtained during continued saline infusions from ter initial collections were performed in hydropenia. seven dogs are included in this report. Dogs were again Furosemide. Furosemide 3 was studied in four hydro- infused with 0.4 ml isotonic saline per kg per minute for penic dogs. In two animals furosemide was administered 30 minutes and then 0.2 ml per kg per minute to the as an initial dose of 5 mg per kg followed by an infu- conclusion of the experiment. sion of the same dose each hour. The other two ani- Reduced filtration rate. The results of reduced filtra- mals received five times this dose. No attempt was tion rate on proximal TF/P inulin ratios during continued made in the furosemide experiments to preserve the ani- saline infusion have also been reported (5). Similarly, mal's sodium balance with isotonic saline infusion. filtration rate was reduced in seven hydropenic dogs by Hydrochlorothiazide. In three dogs, initial collections clamping the left renal artery with a screw clamp. were performed in hydropenia. Hydrochlorothiazide was Urine flow was reduced and the previously punctured administered at a dose of 2 mg per kg initially, followed tubules were resampled.
Recommended publications
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Merck & Co., Inc. V. Biocraft Laboratories, Inc
    Merck & Co., Inc. v. Biocraft Laboratories, Inc., 690 F.Supp. 1376 John J. Francis, Jr., Shanley & Fisher, Morristown, N.J., Joseph M. Fitzpatric, Nicholas M. Cannella, Lawrence Alaburda, Salvatore C. Mitri, Fitzpatrick, Cella, Harper & Scinto, New York City, for plaintiff. Glenn A. Clark, Riker, Danzig, Scherer, Hyland & Perretti, Newark, N.J., Donald R. Dunner, Robert D. Bajefsky, Carol P. Einaudi, Sylvia Blickstein, Legal Asst., Finnegan, Henderson, Farabow, Garrett & Dunner, Washington, D.C., for defendant. OPINION POLITAN, District Judge. Plaintiff, Merck & Co., Inc. ("Merck") is a corporation duly organized and existing under the laws of the State of New Jersey. Merck's principal place of business is at 126 Lincoln Avenue, Rahway, New Jersey. Defendant, Biocraft Laboratories, Inc. ("Biocraft") is a corporation duly organized and existing under the laws of the State of Delaware. Biocraft's principal place of business is at 92 Route 46, Elmwood Park, New Jersey. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. § 1338(a). The parties hereto stipulate that each is subject to personal jurisdiction in the United States District Court for the District of New Jersey. Venue is proper in this district by virtue of 28 U.S.C. § 1400(b). Since its issuance, Merck has been the owner by assignment of the entire right, title and interest in the following United States Letters Patent: Number: 3,781,430 (hereinafter referred as to `430"), Issue Date: 12/25/73, Expiration Date: 12/24/90, Applicant: Edward J. Cragoe, Jr., Title: Diuretic Formulations. The validity of this patent is the subject matter of this litigation.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • ARCI Uniform Classification Guidelines for Foreign Substances, Or Similar State Regulatory Guidelines, Shall Be Assigned Points As Follows
    DRUG TESTING STANDARDS AND PRACTICES PROGRAM. Uniform Classification Guidelines for Foreign Substances And Recommended Penalties Model Rule. January, 2019 (V.14.0) © ASSOCIATION OF RACING COMMISSIONERS INTERNATIONAL – 2019. Association of Racing Commissioners International 2365 Harrodsburg Road- B450 Lexington, Kentucky, USA www.arci.com Page 1 of 66 Preamble to the Uniform Classification Guidelines of Foreign Substances The Preamble to the Uniform Classification Guidelines was approved by the RCI Drug Testing and Quality Assurance Program Committee (now the Drug Testing Standards and Practices Program Committee) on August 26, 1991. Minor revisions to the Preamble were made by the Drug Classification subcommittee (now the Veterinary Pharmacologists Subcommittee) on September 3, 1991. "The Uniform Classification Guidelines printed on the following pages are intended to assist stewards, hearing officers and racing commissioners in evaluating the seriousness of alleged violations of medication and prohibited substance rules in racing jurisdictions. Practicing equine veterinarians, state veterinarians, and equine pharmacologists are available and should be consulted to explain the pharmacological effects of the drugs listed in each class prior to any decisions with respect to penalities to be imposed. The ranking of drugs is based on their pharmacology, their ability to influence the outcome of a race, whether or not they have legitimate therapeutic uses in the racing horse, or other evidence that they may be used improperly. These classes of drugs are intended only as guidelines and should be employed only to assist persons adjudicating facts and opinions in understanding the seriousness of the alleged offenses. The facts of each case are always different and there may be mitigating circumstances which should always be considered.
    [Show full text]
  • Effect of Mersalyl on the Thick Ascending Limb of Henle's Loop
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Kidney International, Vol. 4 (1973). p. 245—251 Effect of mersalyl on the thick ascending limb of Henle's loop MAURICE BURG and NORDICA GREEN Laboratory of Kidney and Electrolyte Metabolism, National Heart andLung Institute, National Institutes of Health, Bethesda, Maryland Effect of mersalyl on the thick ascending limb of Henle's loop. de Henle isolée et perfusee peut être identifié a son effet diuretique The cortical portion of the thick ascending limb of Henle's loop in vivo. Le mersalyl dans Ic bain est inefficace, excepté a une was dissected from rabbit kidneys and perfused in vitro. There concentration plus élevée (10—i M)etalors I'effet n'est pas was active chloride transport resulting in net sodium chloride reversible. Nous concluons que l'effet diurétique des mercuriels reabsorption from the tubule lumen, with the electrical potential est lie, au moms en partie, a l'action inhibitrice de ces drogues difference (PD) oriented positive in the lumen. The addition of sur le transport actif de chlore dans Ia partie large de Ia branche mersalyl ( iO M)tothe lumen caused the PD and net Cl flux ascendante de l'anse de Henle. to decrease, indicating inhibition of the active Cl transport. The decrease in PD caused by the drug in the lumen was approxi- mately 50% at concentrations equal to or greater than iO M, Mercurial diuretics were extensively used and studied andthe decrease in CI transport (measured at 3 x l0 M)was until they were supplanted in the past few years by more similar in magnitude.
    [Show full text]
  • 2021 Equine Prohibited Substances List
    2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s). Prohibited Substances that are identified as Specified Substances in the List below should not in any way be considered less important or less dangerous than other Prohibited Substances. Rather, they are simply substances which are more likely to have been ingested by Horses for a purpose other than the enhancement of sport performance, for example, through a contaminated food substance. LISTED AS SUBSTANCE ACTIVITY BANNED 1-androsterone Anabolic BANNED 3β-Hydroxy-5α-androstan-17-one Anabolic BANNED 4-chlorometatandienone Anabolic BANNED 5α-Androst-2-ene-17one Anabolic BANNED 5α-Androstane-3α, 17α-diol Anabolic BANNED 5α-Androstane-3α, 17β-diol Anabolic BANNED 5α-Androstane-3β, 17α-diol Anabolic BANNED 5α-Androstane-3β, 17β-diol Anabolic BANNED 5β-Androstane-3α, 17β-diol Anabolic BANNED 7α-Hydroxy-DHEA Anabolic BANNED 7β-Hydroxy-DHEA Anabolic BANNED 7-Keto-DHEA Anabolic CONTROLLED 17-Alpha-Hydroxy Progesterone Hormone FEMALES BANNED 17-Alpha-Hydroxy Progesterone Anabolic MALES BANNED 19-Norandrosterone Anabolic BANNED 19-Noretiocholanolone Anabolic BANNED 20-Hydroxyecdysone Anabolic BANNED Δ1-Testosterone Anabolic BANNED Acebutolol Beta blocker BANNED Acefylline Bronchodilator BANNED Acemetacin Non-steroidal anti-inflammatory drug BANNED Acenocoumarol Anticoagulant CONTROLLED Acepromazine Sedative BANNED Acetanilid Analgesic/antipyretic CONTROLLED Acetazolamide Carbonic Anhydrase Inhibitor BANNED Acetohexamide Pancreatic stimulant CONTROLLED Acetominophen (Paracetamol) Analgesic BANNED Acetophenazine Antipsychotic BANNED Acetophenetidin (Phenacetin) Analgesic BANNED Acetylmorphine Narcotic BANNED Adinazolam Anxiolytic BANNED Adiphenine Antispasmodic BANNED Adrafinil Stimulant 1 December 2020, Lausanne, Switzerland 2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s).
    [Show full text]
  • Council of Europe Committee of Ministers (Partial
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies and superseding Resolution AP (77) 1) AND APPENDIX containing the list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 31 October 1982 RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION 1 (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands, the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969 and 5 May 1964, respectively, Considering that, under the terms of its Statute, the aim of the Council of Europe is to achieve a greater unity between its Members for the purpose of safeguarding and realising the ideals and principles which are their common heritage and facilitating their economic and social progress; Having regard to the
    [Show full text]
  • Uniform Classification Guidelines for Foreign Substances, Version 7.00
    Association of Racing Commissioners International, Inc. Drug Testing Standards and Practices Program Model Rules Guidelines Uniform Classification Guidelines for Foreign Substances and Recommended Penalties and Model Rule Version 7.00 Revised January 2014 Association of Racing Commissioners International, Inc. Uniform Classification Guidelines for Foreign Substances Table of Contents Preamble to the Uniform Classification Guidelines of Foreign Substances ..................................................................................... ii Notes Regarding Classification Guidelines ...................................................................................................................................... ii Classification Criteria ....................................................................................................................................................................... iii Classification Definitions ................................................................................................................................................................. iv Drug Classification Scheme ............................................................................................................................................................. vi Alphabetical Substance List ............................................................................................................................................................... 1 Listing by Classification ..................................................................................................................................................................
    [Show full text]